

Europe Melanoma Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2022-11-01 | 254 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

The Europe melanoma cancer diagnostics market is projected to register a substantial CAGR of 6.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Europe Melanoma Cancer Diagnostics Market, By Product Type (Instruments, Consumables and Accessories, and Others), Test Type (Biomarkers Test, Imaging Test, Biopsy, Fluorescent In Situ Hybridization (FISH) Tests, Comparative Genomic Hybridization (CGH) tests, Immunohistochemical (IHC) tests, and Others), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others), Distribution channel (Direct Tender and Retail Sales), Country (Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the Europe melanoma cancer diagnostics market are:

- Rising demand for early melanoma diagnosis
- Increase in the prevalence of melanoma cancer

Market Players:

Some of the major players operating in the Europe melanoma cancer diagnostics market are:

- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- Agilent Technologies, Inc.
- QIAGEN
- F. Hoffman-La Roche Ltd
- Abbott
- Michael Diagnostics Ltd
- NanoString
- Inivata Ltd.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- AMLo Biosciences Limited
- Myriad Genetics, Inc.
- Skin Analytics
- SkylineDx
- NeraCare GmbH
- bioMerieux SA
- Damae Medical

Table of Contents:

TABLE OF CONTENTS

1 INTRODUCTION	48
1.1 OBJECTIVES OF THE STUDY	48
1.2 MARKET DEFINITION	48
1.3 OVERVIEW OF THE EUROPE MELANOMA CANCER DIAGNOSTICS MARKET	48
1.4 LIMITATIONS	50
1.5 MARKETS COVERED	50
2 MARKET SEGMENTATION	53
2.1 MARKETS COVERED	53
2.2 GEOGRAPHICAL SCOPE	54
2.3 YEARS CONSIDERED FOR THE STUDY	55
2.4 CURRENCY AND PRICING	55
2.5 DBMR TRIPOD DATA VALIDATION MODEL	56
2.6 MULTIVARIATE MODELLING	60
2.7 PRODUCT TYPE LIFELINE CURVE	60
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	61
2.9 DBMR MARKET POSITION GRID	62
2.10 MARKET END USER COVERAGE GRID	63
2.11 VENDOR SHARE ANALYSIS	64
2.12 SECONDARY SOURCES	65
2.13 ASSUMPTIONS	65
3 EXECUTIVE SUMMARY	66
4 PREMIUM INSIGHTS	68
4.1 PESTEL'S MODEL	69
4.2 PORTER'S FIVE FORCES MODEL	70
5 EPIDEMIOLOGY	71
6 INDUSTRY INSIGHTS	72
6.1 DEMOGRAPHIC TRENDS	72
6.2 KEY PRICING STRATEGIES	73
6.2.1 PRODUCT INNOVATION	73
6.2.2 CONSUMER AWARENESS	73
6.2.3 A VAST NETWORK OF DISTRIBUTION	73
6.2.4 PARTNERSHIP WITH POPULAR BRANDS BY MAJOR PLAYERS	74
6.2.5 OTHERS	74
6.3 KEY PATIENT ENROLLMENT STRATEGIES	74
6.3.1 IDENTIFICATION OF CUSTOMERS NEED FOR INNOVATIVE DIAGNOSTIC PRODUCTS	74

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.3.2 INCREASING SPECIFIC TACTICS FOR EVERY STEP	74
6.3.3 EDUCATE AND COMMUNICATE	75
6.3.4 IMPROVING DIAGNOSIS SEEKING RATE	75
6.4 INTERVIEWS WITH MANUFACTURING COMPANIES	75
7 MARKET OVERVIEW	77
7.1 DRIVERS	79
7.1.1 GROWING PREVALENCE OF MELANOMA CANCER	79
7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS	80
7.1.3 NOVEL TECHNOLOGIES IN MELANOMA CANCER DIAGNOSTICS	81
7.1.4 INCREASING AWARENESS REGARDING MELANOMA CANCER	82
7.2 RESTRAINTS	82
7.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS	82
7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR MELANOMA CANCERS	83
7.3 OPPORTUNITIES	83
7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR MELANOMA CANCER TREATMENT	83
7.3.2 GOVERNMENT INITIATIVES TOWARD MELANOMA CANCER DIAGNOSTICS	84
7.3.3 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS	85
7.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE	85
7.4 CHALLENGES	86
7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF MELANOMA CANCER DIAGNOSTIC PRODUCTS	86
7.4.2 RADIATION RISKS FROM IMAGING TESTS	86
8 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE	87
8.1 OVERVIEW	88
8.2 INSTRUMENTS	91
8.2.1 IMAGING INSTRUMENTS	92
8.2.1.1 ULTRASOUND SYSTEMS	92
8.2.1.2 MRI SYSTEMS	92
8.2.1.3 CT SYSTEMS	92
8.2.1.4 OTHERS	93
8.2.2 BIOPSY INSTRUMENTS	93
8.2.3 PATHOLOGY-BASED INSTRUMENTS	93
8.2.3.1 PCR INSTRUMENTS	93
8.2.3.2 CELL PROCESSORS	93
8.2.3.3 SLIDE STAINING SYSTEMS	93
8.2.3.4 TISSUE PROCESSING SYSTEMS	94
8.2.3.5 OTHER PATHOLOGY-BASED INSTRUMENTS	94
8.3 CONSUMABLES & ACCESSORIES	94
8.3.1 KITS	95
8.3.1.1 PCR KITS	95
8.3.1.2 NUCLEIC ACID ISOLATION KITS	95
8.3.1.3 DNA POLYMERASE KITS	95
8.3.1.4 OTHERS	96
8.3.2 PROBES	96
8.3.2.1 Q FISH	96
8.3.2.2 FLOW FISH	96
8.3.2.3 OTHERS	96

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.3.3 REAGENTS	96
8.3.3.1 ASSAYS	97
8.3.3.2 BUFFERS	97
8.3.3.3 PRIMERS	97
8.3.3.4 OTHERS	97
8.3.4 OTHER CONSUMABLES	97
8.4 OTHERS	97
9 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE	99
9.1 OVERVIEW	100
9.2 IMAGING TEST	103
9.2.1 ULTRASOUND	104
9.2.2 MRI	104
9.2.3 CHEST X-RAY	104
9.2.4 LYMPHOSCINTIGRAPHY	105
9.2.5 COMPUTED TOMOGRAPHY (CT) SCAN	105
9.2.6 POSITRON EMISSION TOMOGRAPHY (PET) SCAN	105
9.2.7 OTHERS	105
9.3 BIOPSY	105
9.3.1 OPTICAL BIOPSY	106
9.3.2 EXCISIONAL BIOPSY	106
9.3.3 INCISIONAL BIOPSY	106
9.3.4 SHAVE BIOPSY	107
9.3.5 PUNCH BIOPSY	107
9.3.6 OTHERS	107
9.4 IMMUNOHISTOCHEMICAL (IHC) TESTS	107
9.4.1 S100 PROTEIN FAMILY BIOPSY	108
9.4.2 MELAN-A	108
9.4.3 PMEL/PMEL17/SILV/GP100	108
9.4.4 TYROSINASE	108
9.4.5 MITF	108
9.4.6 SM5-1	108
9.4.7 CSPG4/HMW-MAA	108
9.5 BIOMARKER TEST	109
9.5.1 BRAF MUTATION TEST	110
9.5.2 NRAS MUTATION TEST	110
9.5.3 CKIT TEST	110
9.5.4 OTHERS	110
9.6 FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS	110
9.7 COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS	111
9.8 OTHERS	112
10 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER	113
10.1 OVERVIEW	114
10.2 HOSPITALS	117
10.3 ASSOCIATED LABS	118
10.4 DIAGNOSTIC IMAGING CENTERS	118
10.5 INDEPENDENT DIAGNOSTIC LABORATORIES	119
10.6 CANCER RESEARCH INSTITUTES	120

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.7 OTHERS	121
11 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL	122
11.1 OVERVIEW	123
11.2 DIRECT TENDER	126
11.3 RETAIL SALES	126
12 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION	128
12.1 EUROPE	129
12.1.1 GERMANY	139
12.1.2 U.K.	144
12.1.3 FRANCE	149
12.1.4 ITALY	154
12.1.5 RUSSIA	159
12.1.6 NETHERLANDS	164
12.1.7 SPAIN	169
12.1.8 SWEDEN	174
12.1.9 POLAND	179
12.1.10 BELGIUM	184
12.1.11 SWITZERLAND	189
12.1.12 DENMARK	194
12.1.13 NORWAY	199
12.1.14 FINLAND	204
12.1.15 TURKEY	209
12.1.16 REST OF EUROPE	214
13 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE	215
13.1 COMPANY SHARE ANALYSIS: EUROPE	215
14 SWOT ANALYSIS	216
15 COMPANY PROFILE	217
15.1 ABBOTT	217
15.1.1 COMPANY SNAPSHOT	217
15.1.2 REVENUE ANALYSIS	217
15.1.3 COMPANY SHARE ANALYSIS	218
15.1.4 PRODUCT PORTFOLIO	218
15.1.5 RECENT DEVELOPMENTS	218
15.2 ILLUMINA, INC.	219
15.2.1 COMPANY SNAPSHOT	219
15.2.2 REVENUE ANALYSIS	219
15.2.3 COMPANY SHARE ANALYSIS	220
15.2.4 PRODUCT PORTFOLIO	220
15.2.5 RECENT DEVELOPMENT	220
15.3 BIOMERIEUX SA	221
15.3.1 COMPANY SNAPSHOT	221
15.3.2 REVENUE ANALYSIS	221
15.3.3 COMPANY SHARE ANALYSIS	222
15.3.4 PRODUCT PORTFOLIO	222
15.3.5 RECENT DEVELOPMENTS	222
15.4 THERMO FISHER SCIENTIFIC INC.	223
15.4.1 COMPANY SNAPSHOT	223

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.4.2 REVENUE ANALYSIS	223
15.4.3 COMPANY SHARE ANALYSIS	224
15.4.4 PRODUCT PORTFOLIO	224
15.4.5 RECENT DEVELOPMENT	224
15.5 F. HOFFMANN-LA ROCHE LTD.	225
15.5.1 COMPANY SNAPSHOT	225
15.5.2 REVENUE ANALYSIS	225
15.5.3 COMPANY SHARE ANALYSIS	226
15.5.4 PRODUCT PORTFOLIO	226
15.5.5 RECENT DEVELOPMENT	226
15.6 AGILENT TECHNOLOGIES, INC.	227
15.6.1 COMPANY PROFILE	227
15.6.2 REVENUE ANALYSIS	227
15.6.3 PRODUCT PORTFOLIO	228
15.6.4 RECENT DEVELOPMENT	228
15.7 AMLO BIOSCIENCES LIMITED	229
15.7.1 COMPANY PROFILE	229
15.7.2 PRODUCT PORTFOLIO	229
15.7.3 RECENT DEVELOPMENT	229
15.8 CASTLE BIOSCIENCES INC	230
15.8.1 COMPANY SNAPSHOT	230
15.8.2 REVENUE ANALYSIS	230
15.8.3 PRODUCT PORTFOLIO	231
15.8.4 RECENT DEVELOPMENT	231
15.9 DAMAE MEDICAL	232
15.9.1 COMPANY PROFILE	232
15.9.2 PRODUCT PORTFOLIO	232
15.9.3 RECENT DEVELOPMENT	232
15.10 DERMLITE.	233
15.10.1 COMPANY PROFILE	233
15.10.2 PRODUCT PORTFOLIO	233
15.10.3 RECENT DEVELOPMENTS	233
15.11 DERMASENSOR	234
15.11.1 COMPANY PROFILE	234
15.11.2 PRODUCT PORTFOLIO	234
15.11.3 RECENT DEVELOPMENT	234
15.12 DERMTECH	235
15.12.1 COMPANY SNAPSHOT	235
15.12.2 REVENUE ANALYSIS	235
15.12.3 PRODUCT PORTFOLIO	236
15.12.4 RECENT DEVELOPMENT	236
15.13 INIVATA LTD.	237
15.13.1 COMPANY PROFILE	237
15.13.2 PRODUCT PORTFOLIO	237
15.13.3 RECENT DEVELOPMENT	237
15.14 MICHAEL DIAGNOSTICS LTD	238
15.14.1 COMPANY SNAPSHOT	238

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.14.2	PRODUCT PORTFOLIO	238
15.14.3	RECENT DEVELOPMENT	238
15.15	MYRIAD GENETICS, INC.	239
15.15.1	COMPANY SNAPSHOT	239
15.15.2	REVENUE ANALYSIS	239
15.15.3	PRODUCT PORTFOLIO	240
15.15.4	RECENT DEVELOPMENT	240
15.16	NANOSTRING	241
15.16.1	COMPANY SNAPSHOT	241
15.16.2	REVENUE ANALYSIS	241
15.16.3	PRODUCT PORTFOLIO	242
15.16.4	RECENT DEVELOPMENT	242
15.17	NERACARE GMBH	243
15.17.1	COMPANY PROFILE	243
15.17.2	PRODUCT PORTFOLIO	243
15.17.3	RECENT DEVELOPMENT	243
15.18	SKIN ANALYTICS	244
15.18.1	COMPANY PROFILE	244
15.18.2	PRODUCT PORTFOLIO	244
15.18.3	RECENT DEVELOPMENT	244
15.19	SKYLINEDX	245
15.19.1	COMPANY PROFILE	245
15.19.2	PRODUCT PORTFOLIO	245
15.19.3	RECENT DEVELOPMENTS	245

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Europe Melanoma Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2022-11-01 | 254 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2025-05-12
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com